3,653 reports of this reaction
14.1% of all ERLOTINIB HYDROCHLORIDE reports
#1 most reported adverse reaction
DEATH is the #1 most commonly reported adverse reaction for ERLOTINIB HYDROCHLORIDE, manufactured by Armas Pharmaceuticals Inc.. There are 3,653 FDA adverse event reports linking ERLOTINIB HYDROCHLORIDE to DEATH. This represents approximately 14.1% of all 25,894 adverse event reports for this drug.
Patients taking ERLOTINIB HYDROCHLORIDE who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is a frequently reported adverse event for ERLOTINIB HYDROCHLORIDE, accounting for a significant proportion of all reports.
In addition to death, the following adverse reactions have been reported for ERLOTINIB HYDROCHLORIDE:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 3,653 FDA reports for ERLOTINIB HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 14.1% of all adverse event reports for ERLOTINIB HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience death while taking ERLOTINIB HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.